These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 27713622)

  • 1. Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment.
    Garcia-Dominguez JM; Muñoz D; Comellas M; Gonzalbo I; Lizán L; Polanco Sánchez C
    Patient Prefer Adherence; 2016; 10():1945-1956. PubMed ID: 27713622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decision Making About Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis: Stated Preferences and Real-World Choices.
    Webb EJD; Meads D; Eskytė I; Ford HL; Bekker HL; Chataway J; Pepper G; Marti J; Okan Y; Pavitt SH; Schmierer K; Manzano A
    Patient; 2023 Sep; 16(5):457-471. PubMed ID: 37072663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment.
    Poulos C; Kinter E; Yang JC; Bridges JF; Posner J; Reder AT
    Patient; 2016 Apr; 9(2):171-80. PubMed ID: 26259849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients' preferences and willingness-to-pay for disease-modifying therapies.
    Frost N; Freeman J; Brixner D; Mort J; Clem J; Ngorsuraches S
    Mult Scler Relat Disord; 2019 Oct; 35():55-60. PubMed ID: 31323483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conjoint analysis to understand preferences of patients with multiple sclerosis for disease-modifying therapy attributes in Spain: a cross-sectional observational study.
    Arroyo R; Sempere AP; Ruiz-Beato E; Prefasi D; Carreño A; Roset M; Maurino J
    BMJ Open; 2017 Mar; 7(3):e014433. PubMed ID: 28274968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world treatment preferences among health care providers in the United States in selecting disease modifying therapies for patients with multiple sclerosis: a discrete choice experiment.
    Bandari D; Adamson M; Bowman M; Gutierrez A; Athavale A; Oak B; Hadker N; Branco F; Geremakis C; Lewin JB; Shankar SL
    J Med Econ; 2023; 26(1):1507-1518. PubMed ID: 37934412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments.
    Webb EJD; Meads D; Eskytė I; Ford HL; Bekker HL; Chataway J; Pepper G; Marti J; Okan Y; Pavitt SH; Schmierer K; Manzano A
    Patient; 2020 Oct; 13(5):583-597. PubMed ID: 32588337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment preferences in relation to fatigue of patients with relapsing multiple sclerosis: A discrete choice experiment.
    Tervonen T; Fox RJ; Brooks A; Sidorenko T; Boyanova N; Levitan B; Hennessy B; Phillips-Beyer A
    Mult Scler J Exp Transl Clin; 2023; 9(1):20552173221150370. PubMed ID: 36714174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis.
    Poudel N; Banjara B; Kamau S; Frost N; Ngorsuraches S
    Mult Scler Relat Disord; 2021 Feb; 48():102720. PubMed ID: 33429304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany.
    Poulos C; Kinter E; Yang JC; Bridges JF; Posner J; Gleißner E; Mühlbacher A; Kieseier B
    Ther Adv Neurol Disord; 2016 Mar; 9(2):95-104. PubMed ID: 27006697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis.
    Utz KS; Hoog J; Wentrup A; Berg S; Lämmer A; Jainsch B; Waschbisch A; Lee DH; Linker RA; Schenk T
    Ther Adv Neurol Disord; 2014 Nov; 7(6):263-75. PubMed ID: 25371708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
    Neuberger EE; Abbass IM; Jones E; Engmann NJ
    Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PREFERENCES OF PATIENTS WITH MULTIPLE SCLEROSIS FOR ATTRIBUTES OF INJECTABLE MULTIPLE SCLEROSIS TREATMENTS IN THE UNITED KINGDOM AND FRANCE.
    Poulos C; Kinter E; van Beek J; Christensen K; Posner J
    Int J Technol Assess Health Care; 2018 Jan; 34(4):425-433. PubMed ID: 30251947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Summarizing Patient Preferences for the Competitive Landscape of Multiple Sclerosis Treatment Options.
    Jonker MF; Donkers B; Goossens LMA; Hoefman RJ; Jabbarian LJ; de Bekker-Grob EW; Versteegh MM; Harty G; Wong SL
    Med Decis Making; 2020 Feb; 40(2):198-211. PubMed ID: 32065023
    [No Abstract]   [Full Text] [Related]  

  • 15. An international discrete choice experiment assessing patients' preferences for disease-modifying therapy attributes in multiple sclerosis.
    Bauer B; Brockmeier B; Devonshire V; Charbonne A; Wach D; Hendin B
    Neurodegener Dis Manag; 2020 Dec; 10(6):369-382. PubMed ID: 32873160
    [No Abstract]   [Full Text] [Related]  

  • 16. Factors Associated with Patient Preferences for Disease-Modifying Therapies in Multiple Sclerosis.
    Hincapie AL; Penm J; Burns CF
    J Manag Care Spec Pharm; 2017 Aug; 23(8):822-830. PubMed ID: 28737987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient centered decision making: use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices.
    Wilson L; Loucks A; Bui C; Gipson G; Zhong L; Schwartzburg A; Crabtree E; Goodin D; Waubant E; McCulloch C
    J Neurol Sci; 2014 Sep; 344(1-2):80-7. PubMed ID: 25037284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing Pharmacists' Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis.
    Martínez-López I; Maurino J; Sanmartín-Fenollera P; Ontañon-Nasarre A; Santiago-Pérez A; Moya-Carmona I; García-Collado CG; Fernández-Del Olmo R; García-Arcelay E; Sarmiento M; Carreño Á; Pérez-Encinas M
    Pharmacy (Basel); 2020 Apr; 8(2):. PubMed ID: 32272683
    [No Abstract]   [Full Text] [Related]  

  • 19. Using a multidimensional unfolding approach to assess multiple sclerosis patient preferences for disease-modifying therapy: a pilot study.
    Sempere AP; Vera-Lopez V; Gimenez-Martinez J; Ruiz-Beato E; Cuervo J; Maurino J
    Patient Prefer Adherence; 2017; 11():995-999. PubMed ID: 28615928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient and Neurologist Preferences in the United States for Relapsing-Remitting Multiple Sclerosis Treatments: Findings from a Discrete Choice Experiment.
    Kumar J; Cambron-Mellott MJ; Tencer T; Will O; Mackie DS; Beusterien K
    Patient Prefer Adherence; 2021; 15():1515-1527. PubMed ID: 34267507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.